KTH Royal Institute of Technology   Report issue

Academic/Hospital Phase 2
Founded: Stockholm Sweden (1827)

Organization Overview

First Clinical Trial
2016
NCT04324346
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

KTH Royal Institute of Technology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Fatty Liver (Phase 2)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 6